Rigel Pharmaceuticals, Inc.

( )
RIGL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.01%177.180.7%$1153.99m
LLYEli Lilly & Co. -0.05%371.791.1%$1049.81m
MRKMerck & Co., Inc. 0.70%110.860.7%$1003.98m
PFEPfizer Inc. 3.12%51.810.9%$984.69m
ABBVAbbVie, Inc. 0.28%165.871.9%$890.99m
BMYBristol-Myers Squibb Co. 0.00%79.931.1%$735.65m
AZNAstraZeneca Plc 0.47%69.171.0%$348.90m
HZNPHorizon Therapeutics Plc 0.63%96.915.4%$294.05m
GSKGSK Plc -0.77%36.600.3%$252.86m
IDXXIDEXX Laboratories, Inc. 2.01%428.543.9%$192.93m
NVSNovartis AG -0.15%91.590.2%$184.83m
ALNYAlnylam Pharmaceuticals, Inc. 2.89%238.018.0%$173.86m
CTLTCatalent, Inc. -3.53%45.561.9%$170.36m
NVONovo Nordisk A/S 2.08%127.840.1%$148.14m
SNYSanofi -2.13%46.920.2%$140.27m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.